Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancer constitutes a grave problem nowadays in view of the fact that it has become one of the main causes of death worldwide. Poor clinical prognosis is presumably due to cancer cells metabolism as tumor microenvironment is affected by oxidative stress. This event triggers adequate cellular response and thereby creates appropriate conditions for further cancer progression. Endoplasmic reticulum (ER) stress occurs when the balance between an ability of the ER to fold and transfer proteins and the degradation of the misfolded ones become distorted. Since ER is an organelle relatively sensitive to oxidative damage, aforementioned conditions swiftly cause the activation of the unfolded protein response (UPR) signaling pathway. The output of the UPR, depending on numerous factors, may vary and switch between the pro-survival and the pro-apoptotic branch, and hence it displays opposing effects in deciding the fate of the cancer cell. The role of UPR-related proteins in tumorigenesis, such as binding the immunoglobulin protein (BiP) and inositol-requiring enzyme-1α (IRE1α), activating transcription factor 6 (ATF6) or the protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), has already been specifically described so far. Nevertheless, due to the paradoxical outcomes of the UPR activation as well as gaps in current knowledge, it still needs to be further investigated. Herein we would like to elicit the actual link between neoplastic diseases and the UPR signaling pathway, considering its major branches and discussing its potential use in the development of a novel, anti-cancer, targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase
Harding, H. P., Zhang, Y., & Ron, D. (1999) · Nature · doi:10.1038/16729 · Cited by 3,310 · cited 1×
“Subsequently, PERK-dependent phosphorylation of eIF2α follows, which results in a transient block of global mRNA translation to decrease the protein-folding demand in the ER [73,74].”
BackgroundDynamic interaction of BiP and ER stress transducers in the unfolded-protein response
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000) · Nature Cell Biology · doi:10.1038/35014014 · Cited by 2,860
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis
Lei, K., & Davis, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438011100 · Cited by 1,068 · cited 2×
“JNK may downregulate anti-apoptotic proteins such as BCL-2, BAD or BAX [124,125], with parallel activation of pro-apoptotic BID, BIM and Bcl-2-modifying factor (BMF), all of which belong to so-called BH3-only family [126,127].”
BackgroundFestjens, N., Vanden Berghe, T., & Vandenabeele, P. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.06.014 · Cited by 710
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662
Sivandzade, F., Prasad, S., Bhalerao, A., & Cucullo, L. (2019) · Redox Biology · doi:10.1016/j.redox.2018.11.017 · Cited by 639 · cited 3×
“However, excessive ROS generation (both endogenous and exogenous) may directly evoke redox imbalance and consequential cellular and tissue damage [94].”
BackgroundThe Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633
Moreno, J. A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J. M., Ortori, C. A., Willis, A. E., Fischer, P. M., Barrett, D. A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006767 · Cited by 589
Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway
Cullinan, S. B., & Diehl, J. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.018 · Cited by 554
Self-citationThe BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
The KEAP1–NRF2 System in Cancer
Taguchi, K., & Yamamoto, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00085 · Cited by 527 · cited 1×
“Thus, Nrf2-Keap1 is considered the main signaling pathway activated to restore redox balance [96].”
BackgroundCharacterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3109 · Cited by 443 · cited 2×
“However, despite the GSK2656157 anti-tumor activity, it also significantly inhibited pancreatic function, as well as after GSK2656157 withdrawal the anti-tumor activity was reversed [284].”
BackgroundMimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood · doi:10.1182/blood-2011-07-366633 · Cited by 432 · cited 1×
“Nevertheless, the inhibition of IRE1α has already demonstrated positive therapeutic outcomes in Ewing′s sarcoma [168], MM [169], acute myeloid leukemia (AML) [170] as well as triple-negative breast cancer (TNBC) [165].”
BackgroundATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner
Chen, D., Fan, Z., Rauh, M., Buchfelder, M., Eyupoglu, I. Y., & Savaskan, N. (2017) · Oncogene · doi:10.1038/onc.2017.146 · Cited by 421 · cited 2×
“The fact that overexpression of ATF4 aggravates malignant phenotypes has also been confirmed in the case of high-grade gliomas (HGG), wherein it evokes increased proliferation, angiogenesis, and tumor cell migration [79].”
BackgroundIRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
Song, M., Sandoval, T. A., Chae, C.-S., Chopra, S., Tan, C., Rutkowski, M. R., Raundhal, M., Chaurio, R. A., Payne, K. K., Konrad, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0597-x · Cited by 413
Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2
Ma, Q., & He, X. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004333 · Cited by 317 · cited 2×
“Nrf2 is also responsible for enhanced expression of ATP-binding cassette (ABC) transporters, including multidrug resistance-associated protein (MRP) family members, which determine efflux of ions, toxins and signal transduction [92], and xenobiotic-activated receptor (XAR), capable of activating the antioxidant respon…”
BackgroundBioavailability challenges associated with development of anti-cancer phenolics
Gao, S., & Hu, M. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384081 · Cited by 242
Rojas-Rivera, D., Delvaeye, T., Roelandt, R., Nerinckx, W., Augustyns, K., Vandenabeele, P., & Bertrand, M. J. M. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.58 · Cited by 206 · cited 2×
“[286] has demonstrated that both GSK2606414 and GSK2656157, commonly used as inhibitors of the PERK-dependent UPR signaling pathway, trigger complete inhibition of the TNF-mediated receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-dependent cell death in the nanomolar range and the above-mentioned inhibit…”
BackgroundZhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09263-1 · Cited by 161
Aggarwal, P., Lessie, M. D., Lin, D. I., Pontano, L., Gladden, A. B., Nuskey, B., Goradia, A., Wasik, M. A., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2007) · Genes & Development · doi:10.1101/gad.1586007 · Cited by 132 · cited 1×
“This phenomenon can be explained by overexpression of cyclin D1 and repression of CHOP translation in PERK+/− mutant cells [220,221].”
BackgroundSelf-citationNakagawa, H., Hirata, Y., Takeda, K., Hayakawa, Y., Sato, T., Kinoshita, H., Sakamoto, K., Nakata, W., Hikiba, Y., Omata, M., et al. (2011) · Hepatology · doi:10.1002/hep.24357 · Cited by 86
Cited by
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Self-citationEndoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link
Nie, Z., Chen, M., Wen, X., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Ni, J., & Zhang, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683940 · Cited by 43
Ben Othmène, Y., Monceaux, K., Belhadef, A., Karoui, A., Ben Salem, I., Boussabbeh, M., Abid-Essefi, S., & Lemaire, C. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103919 · Cited by 43
Metadata
- Authors
- Siwecka, N., Rozpędek, W., Pytel, D., Wawrzynkiewicz, A., Dziki, A., Dziki, Ł., Diehl, J. A., & Majsterek, I.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-05
- Volume
- 20
- Issue
- 18
- Pages
- 4354
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2971914964
- Cited by
- 200
- References
- 24
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.